A Randomized 4 Week Phase IIa Trial Evaluating the Efficacy, Safety, and Tolerability of GRT6005, a New Centrally Acting Analgesic, in Subjects With Moderate to Severe Pain Due to Osteoarthritis (OA) of the Knee.

Trial Profile

A Randomized 4 Week Phase IIa Trial Evaluating the Efficacy, Safety, and Tolerability of GRT6005, a New Centrally Acting Analgesic, in Subjects With Moderate to Severe Pain Due to Osteoarthritis (OA) of the Knee.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Cebranopadol (Primary)
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Pharmacogenomic; Therapeutic Use
  • Sponsors Grunenthal
  • Most Recent Events

    • 16 Jun 2017 A population PK analysis of cebranopadol using data from phase I and II trials, results published in the Clinical Pharmacokinetics
    • 28 Mar 2012 Additional tria location (Austria) added as reported as European Clinical Trials Database.
    • 22 Dec 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top